Journal Pre-proof



Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

Annika Fendler, Scott T.C. Shepherd, Lewis Au, Mary Wu, Ruth Harvey, Katalin A. Wilkinson, Andreas M. Schmitt, Zayd Tippu, Benjamin Shum, Sheima Farag, Aljosja Rogiers, Eleanor Carlyle, Kim Edmonds, Lyra Del Rosario, Karla Lingard, Mary Mangwende, Lucy Holt, Hamid Ahmod, Justine Korteweg, Tara Foley, Taja Barber, Andrea Emslie-Henry, Niamh Caulfield-Lynch, Fiona Byrne, Daqi Deng, Svend Kjaer, Ok-Ryul Song, Christophe J. Queval, Caitlin Kavanagh, Emma C. Wall, Edward J. Carr, Simon Caidan, Mike Gavrielides, James I. MacRae, Gavin Kelly, Kema Peat, Denise Kelly, Aida Murra, Kayleigh Kelly, Molly O'Flaherty, Robyn L. Shea, Gail Gardner, Darren Murray, Sanjay Popat, Nadia Yousaf, Shaman Jhanji, Kate Tatham, David Cunningham, Nicholas Van As, Kate Young, Andrew J.S. Furness, Lisa Pickering, Rupert Beale, Charles Swanton, Sonia Gandhi, Steve Gamblin, David L.V. Bauer, George Kassiotis, Michael Howell, Emma Nicholson, Susanna Walker, Robert J. Wilkinson, James Larkin, Samra Turajlic, on behalf of the CAPTURE consortium

PII: S2666-3791(22)00336-6

DOI: https://doi.org/10.1016/j.xcrm.2022.100781

Reference: XCRM 100781

To appear in: *Cell Reports Medicine*

Received Date: 6 June 2022

Revised Date: 7 September 2022

Accepted Date: 21 September 2022

Please cite this article as: Fendler, A., Shepherd, S.T.C., Au, L., Wu, M., Harvey, R., Wilkinson, K.A., Schmitt, A.M., Tippu, Z., Shum, B., Farag, S., Rogiers, A., Carlyle, E., Edmonds, K., Del Rosario, L., Lingard, K., Mangwende, M., Holt, L., Ahmod, H., Korteweg, J., Foley, T., Barber, T., Emslie-Henry, A., Caulfield-Lynch, N., Byrne, F., Deng, D., Kjaer, S., Song, O.-R., Queval, C.J., Kavanagh, C., Wall, E.C., Carr, E.J., Caidan, S., Gavrielides, M., MacRae, J.I, Kelly, G., Peat, K., Kelly, D., Murra, A., Kelly, K., O'Flaherty, M., Shea, R.L., Gardner, G., Murray, D., Popat, S., Yousaf, N., Jhanji, S., Tatham, K., Cunningham, D., Van As, N., Young, K., Furness, A.J.S., Pickering, L., Beale, R., Swanton, C., Gandhi, S., Gamblin, S., Bauer, D.L.V., Kassiotis, G., Howell, M., Nicholson, E., Walker, S., Wilkinson, R.J., Larkin, J., Turajlic, S., on behalf of the CAPTURE consortium, Functional immune responses against

SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer, *Cell Reports Medicine* (2022), doi: https://doi.org/10.1016/j.xcrm.2022.100781.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 The Author(s).

Journal Pre-proof

CAPTURE Study



Neutralising antibody (NAb) titres



↑ NAb following 4th dose
↓ NAb B cell depleting Tx
↑ NAb to BA1 & BA.2

T cell activation assay

WT spike peptides
omicron spike peptides

Activation following 4th dose
Anti-spike & omicron activation

Journal Pre-proof

Journal Pre-proof

Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

Annika Fendler[1,34], Scott T.C. Shepherd[1,2,34], Lewis Au[1,2,33], Mary Wu[3,33], Ruth Harvey[4,33], Katalin A. Wilkinson[5,6,33], Andreas M. Schmitt[2], Zayd Tippu[1,2], Benjamin Shum[1,2], Sheima Farag[2], Aljosja Rogiers[2], Eleanor Carlyle[2], Kim Edmonds[2], Lyra Del Rosario[2], Karla Lingard[2], Mary Mangwende[2], Lucy Holt[2], Hamid Ahmod[2], Justine Korteweg[2], Tara Foley[2], Taja Barber[1], Andrea Emslie-Henry[1], Niamh Caulfield-Lynch[1], Fiona Byrne[1], Daqi Deng[1], Svend Kjaer[7], Ok-Ryul Song[8], Christophe J. Queval[8], Caitlin Kavanagh[3], Emma C. Wall[3,8], Edward J. Carr[10], Simon Caidan[11], Mike Gavrielides[12], James I MacRae[13], Gavin Kelly[14], Kema Peat[2], Denise Kelly[2], Aida Murra[2], Kayleigh Kelly[2], Molly O'Flaherty[2], Robyn L. Shea[15,16], Gail Gardner[15], Darren Murray[15], Sanjay Popat[17], Nadia Yousaf[17,18], Shaman Jhanji[19], Kate Tatham[19], David Cunningham[20], Nicholas Van As[21], Kate Young[2], Andrew J.S. Furness[2], Lisa Pickering[2], Rupert Beale[10,22], Charles Swanton[23,24], Sonia Gandhi[25,26], Steve Gamblin[27], David L.V. Bauer[28], George Kassiotis[29], Michael Howell[8], Emma Nicholson[30,31], Susanna Walker[19], Robert J. Wilkinson[5,6,32], James Larkin[2,33], Samra Turajlic[1,2,33,35,36] on behalf of the CAPTURE consortium

[1]Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

[2]Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK

[3]COVID Surveillance Unit, The Francis Crick Institute, London, NW1 1AT, UK

[4]Worldwide Influenza Centre, The Francis Crick Institute, London, NW1 1AT, UK

[5]Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

[6]Wellcome Center for Infectious Disease Research in Africa, University Cape Town, Observatory 7925, Republic of South Africa

[7] Structural Biology Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK

[8]High Throughput Screening Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

[9]University College London Hospitals NHS Foundation Trust Biomedical Research Centre, London, WC1E 6BT, UK

[10]Cell Biology of Infection Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

[11]Safety, Health & Sustainability, The Francis Crick Institute, London, NW1 1AT, UK

[12]Scientific Computing Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK

[13]Metabolomics Scientific Technology Platform, The Francis Crick Institute, London, NW1 1AT, UK

[14]Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.

[15]Department of Pathology, The Royal Marsden NHS Foundation Trust, London, NW1 1AT, UK

Journal Pre-proof

Journal Pre-proof

[16]Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research, London, SW7 3RP, UK

[17]Lung Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK

[18]Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK

[19]Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK

[20]Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey SM2 5PT

[21]Clincal Oncology Unit, The Royal Marsden NHS Foundation Trust, London, NW1 1AT, UK

[22]Division of Medicine, University College London, London NW1 2PG, UK

[23]Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

[24]University College London Cancer Institute, London WC1E 6DD, UK

[25]Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

[26]UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG

[27] Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

[28]RNA Virus Replication Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

[29]Retroviral Immunology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

[30]Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK

[31]Haemato-oncology Unit, The Institute of Cancer Research, London, SW7 3RP, UK

[32]Department of Infectious Disease, Imperial College London, London, W2 0NN, UK

[33]Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London, SW7 3RP, UK

[34]These authors contributed equally

[35]Corresponding author

[36]Lead contact

Running title: Fourth COVID-19 vaccine or infection in patients with blood cancer

Keywords: COVID-19, SARS-COV-2, blood cancer, variants of concern, neutralising antibodies, T cells

Lead contact & corresponding author: Dr Samra Turajlic

Telephone: +44 020 37961111

E-mail: samra.turajlic@crick.ac.uk

Word count: 14376 characters excluding material and methods

Journal Pre-proof

Number of tables: 3

Number of figures: 1

Journal Pre-proof

Journal Pre-proof

SUMMARY

Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886) we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralising antibody titres (NAbT) using a live virus microneutralization assay against wild-type (WT), Delta, Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titres and T cell responses after the fourth vaccine dose increases compared to those after the third vaccine dose. Patients who received B cell-depleting therapies within 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.

Journal Pre-proof

Journal Pre-proof

INTRODUCTION

A third COVID-19 vaccine doses induces functional immune responses in most patients with cancer, including neutralising antibodies (NAb) against variants of concern (VOC) and T cell responses. However, some of patients with blood cancer, especially those receiving B cell-depleting therapies have inadequate immune responses even after a third dose [1, 2] and may in turn have a higher risk of breakthrough infection. Regarding the Omicron BA.1 variant, NAb response increased after three doses in patients with solid cancer, but a substantial proportion of patients with blood cancer still lacked NAb responses against Omicron BA.1 [3, 4]. Additional sublineages with immune evasive properties, such as BA.4. and BA.5 are now prevalent in many countries, including UK [5]. Amid widespread lifting of COVID-19 public health measures and high rates of community transmission of Omicron, a significant proportion of COVID-19 deaths still occur in patients with blood cancer [6]. In the U.K., a fourth vaccine dose was recommended in December 2021 for patient groups, including patients with blood cancer. It remains unknown whether this has an impact on those with suboptimal responses following three doses.

Here we report the follow-up findings from CAPTURE – a prospective longitudinal cohort study assessing the functional immune responses to COVID vaccinations in patients with cancer. We report immune responses in patients with blood cancer that has received a fourth vaccine dose in December 2021 to February 2022. Longitudinal sampling within CAPTURE to identify patients with breakthrough infections (BTI) and to describe their NAb responses before and after infection.

RESULTS

We evaluated 80 patients with blood cancer who received a third and fourth dose of BNT162b2 after two doses of ChAdOx1 (n=45, 56%) or BNT162b2 (n=35, 44%) (**Table 1**). Furthermore, we evaluated 51 patients (n=40 solid cancer, n=11 blood cancer) with breakthrough infection (BTI) at least seven days following the second or third dose of the COVID-19 vaccine (**Table 2**).

Journal Pre-proof

The breakdown of patients who received a fourth vaccine dose was (**Table 1**) lymphoma (n=21), acute leukaemia (n=7), myeloma (n=33), chronic lymphocytic leukaemia (n=16), and myelodysplastic syndromes (n=3). 15% of the patients (n=12) had confirmed past COVID-19 infection (all prior to the second vaccine dose). Matched post-third and post-fourth dose blood samples were available for 76/80 patients. Blood was collected at a median of 28 days (range: 8-60 days) after the third dose and 18 days (range: 6-67 days) following the fourth dose. NAb were measured using an established micro-neutralisation assay [7-9], and IC50 titres (NAbT) of <40 (below the quantitative range) were considered undetectable.

Following three vaccine doses, 62% (47/76) of patients with blood cancer had detectable NAbT against Omicron BA.1, compared to 87% (66/76) against wild-type SARS-CoV-2 (Wuhan, hereafter WT) (McNemar test, $p < 0.0001$), and 72% (55/76) against Delta (McNemar test, $p = 0.013$). Following the fourth vaccine dose, the proportion of patients with detectable NAbT against Omicron BA.1 was 79% (63/80) compared to 98% (78/80) against WT (McNemar test, $p = 0.0003$) and 78% (62/80) against Delta (McNemar test, $p = 1$). Significant differences in the proportion of patients with detectable NAbT after three vs four vaccine doses were apparent for Omicron BA.1 (McNemar test, $p = 0.0015$) and WT (McNemar test, $p = 0.013$) but not for Delta (McNemar test, $p = 0.51$) (**Figure 1A**).

The BA.1 Omicron sublineage was followed by the several other sublineages (BA.2, BA.4, BA.5). Comparable NAb responses were observed for BA.1 and BA.2 in individuals without cancer (Yamasoba et al., 2022). In our cohort, following four vaccine doses, 90% (72/80) of patients with blood cancer had detectable NAbT against BA.2, which was higher than the proportion with Nab against BA.1 (McNemar test, $p = 0.008$) (**Figure 1B**).

Multivariable logistic regression analysis (MVA, **Table 3**) showed that patients treated with B cell-depleting therapies were at a higher risk of having undetectable NAbT against Omicron BA.1 or BA.2 sublineages after four vaccine doses (anti-CD20 [n=11] and BTKi [n=4], BA.1: OR [95%CI]: 0.03 [0.003-0.14], p=0.0013], BA.2: OR [95%CI]: 0.06 [0.004-0.41], p=0.03]). The association of B cell-depleting therapies with low antibody titres was confirmed in an ordinal logistic regression model with

Journal Pre-proof

NAbT split into three categories (undetectable (<=40), moderate (>40-256), and high (>256) (Table S1 and S2). Only 3/11 and 7/11 of patients treated with anti-CD20 within 12 months prior to vaccination and 2/4 and 3/4 patients treated with BTKi within 28 days prior to vaccination had detectable NAbT against Omicron BA.1 and BA.2 after four vaccine doses, respectively.

$CD4^+$ and $CD8^+$ T cell responses were analysed using an activation-induced marker assay (AIM assay, using CD137 and OX40 as markers for $CD4^+$ T cell activation and CD137 and CD69 as markers for $CD8^+$ T cell activation) after stimulation with a peptide pool against full-length WT spike or Omicron spike in 39/80 patients with blood cancer (**Table 1**). T cell responses were considered positive if a 2-fold increase in AIM+ T cells was detected after peptide stimulation vs. unstimulated control [10]. 32/39 (82%) of patients were evaluable and had matched samples after the third and fourth dose

Considering T cell responses against Omicron spike, 31% (10/32) of patients with blood cancer had $CD4^+$ T cell responses after three doses compared to 59% (19/32) after four doses (McNemar test, p = 0.0077) **(Figure 1C)**, while 34% (11/32) had $CD8^+$ T cell responses after three and 44% (14/32) after four doses (McNemar test, p = 0.51) **(Figure 1D)**. Considering T cell responses to the WT spike, 59% (19/32) of patients had $CD4^+$ T cell responses after three vaccine doses compared to 81% (26/32) after four doses (McNemar test, p = 0.045); while the proportion of those with $CD8^+$ T cell responses did not change (56% (18/32) after three and four vaccine doses (McNemar test, p = 1)).

Taken together, these data indicate that patients with blood cancer benefit from a fourth vaccine dose which increases in the proportion of patients with NAb and T cell responses against VOCs.

Within CAPTURE, we identified 57 participants (n=41 solid cancer, n=16 blood cancer) with breakthrough infection, defined here as a positive SARS-CoV-2 RT PCR and/or lateral flow antigen test at least seven days following the second COVID-19 vaccine. All infections were detected during routine clinical care, following two vaccine doses (36 patients, n=33 solid cancer, n=3 blood cancer), or three or four vaccine doses (21 patients, n=8 solid cancer, n=13 blood cancer) (**Table 2**).

The median time from the most recent vaccine dose to infection was 79 days (IQR 66-139). Most patients had mild COVID-19 (n=42/57; WHO score 2-3) (Marshall et al., 2020). The most common

Journal Pre-proof

symptoms were cough (n=29), fever (n=22), or coryza (n=20); and nine patients were asymptomatic (WHO score 1). Six patients had moderate (n=2, WHO score 4-6) or severe COVID-19 (n=4, WHO score 7-10) requiring hospitalisation and treatment with oxygen therapy (n=5), corticosteroids (n=5) and IL-6 monoclonal antibodies (n=3). Four patients died within 28 days of a positive SARS-CoV-2 test. Eight patients with blood cancer received antiviral therapies or monoclonal antibodies (remdesivir n=4; molnupiravir n=2; sotrovimab n=2) for treatment of acute SARS-CoV-2 infection. Patients with BTI following the second dose considered as being infected with the Delta variant given the high prevalence of this variant at the time. In contrast, 19/21 patients infected following the third vaccine dose were infected from December 2021 onwards at the peak of the Omicron wave and these infections were subsequently considered as Omicron infections.

Convalescent blood samples were available for 51/57 patients (n=36 infected after the second dose, and n=15 infected after the third dose). During convalescence, 32/36 patients with BTI after two doses had detectable NAbT against Delta **(Figure 1E-F)**. Following the third dose, 15/15 patients had detectable NAbT against Omicron after infection **(Figure 1E and G)**. NAbT against WT were detected in all but one patients (after two vaccine doses) before infection. In addition, blood samples between the most recent vaccine and infection were available in 25 patients (n=12 infected after second dose, n=13 infected after third dose) (**Figure 1E**). 8/12 patients infected after two vaccine doses had undetectable NAbT against Delta or NAbT declined before infection **(Figure 1F) and** 8/13 patients infected after three doses had undetectable NAbT against Omicron before infection **(Figure 1G)**.

Notably, patients with Delta and Omicron BTI had evidence of a degree of boosting cross-reactive neutralising responses against the other variants, consistent with previous reports that cross-reactivity is observed in previously vaccinated patients [11]. Of the three patients with no detectable convalescent NAb, two were blood cancer patients with severe COVID-19 who later died, and one patient had a solid cancer with mild COVID-19. In summary, our data are consistent with published data in healthy individuals[12] that low variant-specific NAb responses may contribute to infection risk.

Journal Pre-proof

DISCUSSION

We demonstrate that patients with blood cancer can benefit from a fourth vaccine dose, even if they had an undetectable response after three doses, especially when considering immune responses to Omicron BA.1 or BA.2. In a cohort of health care workers, a fourth dose of BNT162b2 after three doses of the same vaccine elicited an increase in spike and neutralising titres, surpassing titres immediately after third dose [13]. Our data show a nuanced picture in patients with blood cancer, where especially NAbT against Omicron (which were undetectable in a substantial proportion after the third dose) were increased by the fourth dose. These findings highlight the need to consider variant-specific responses in determining which patients may benefit from additional vaccine doses or therapies using antiviral prophylaxis or monoclonal antibodies. Recent reports confirmed a higher risk of Omicron breakthrough infections when compared to Delta breakthrough infections in both individuals with and without cancer, likely resulting from Omicron escaping vaccine-induced immunity [14, 15]. In keeping with these findings, we observed both Delta and Omicron breakthroughs in our cohort, which were associated with low NAb titres against the respective variant.

Our study has several limitations. Firstly, the heterogeneity and size of the cohort limits subgroup analyses and specific studies in each cancer type are needed to define risk factors for low NAb responses beyond B cell-depleting therapies and to define the determinants of T cell responses. Second, the precise correlate of protection from breakthrough infection remains undefined, and prospective studies are needed for to accurately estimate infection risk after three and four vaccine doses in patients with blood cancer. Reports after three vaccine doses confirm the high clinical efficacy of COVID-19 vaccines in the general population and elderly individuals [16-19] and an additional benefit in older and at-risk individuals who had received a fourth dose [20, 21]. Comparable data are currently lacking in patients with cancer, but our observations in patient with BTI agree with models and data in healthy populations suggesting a direct association of NAbT with infection risk[12, 22], although

Comparable data are currently lacking in patients with cancer; while our observations in BTI agree with models and data in healthy populations suggesting a direct association of NAbT with infection risk our study was not designed to definitively address a direct association. Third, we have not generated data on NAbT the omicron subvariants BA.4 and BA.5 have become the prevalent circulating variants in a number of countries, including the UK [5]. Reports indicate that while booster vaccination increases responses to all omicron sublineages, BA.4 and BA.5 show greater immune escape, therefore patients with blood cancer will likely have less protection against these variants [23-25].

Overall, our data highlight the benefit of a fourth vaccine doses in patients with blood cancer and confirm that patients with B cell-depleting therapies are at the highest at risk of having impaired NAb responses.

Limitations of the Study

We acknowledge limitations of our study. First, cohort size and heterogeneity limited subgroup analyses and larger and/or subtype or treatment specific cohorts are needed to evaluate immune responses in particular groups. Second, we were unable to directly assess immune responses to the omicron sublineages BA.4 and BA.5, these are circulating in many countries and have been reported to show greater degree of immune escape that BA.1 and BA.2 sublineages. Finally, our study did not include proactive monitoring for breakthrough infection which likely led to their under-representation, in particular asymptomatic infections. While the aim of our study was not to define precise correlates of immune protection, a means to identify patients with suboptimal protection should be a priority for the community. Prospective, adequately powered studies to address this are especially important in view of updated vaccine design and in the context of emergent variants.

Journal Pre-proof

Journal Pre-proof

ACKNOWLEDGMENTS

We thank the clinical leads and subunit teams for recruiting patients to the study, including F. Gronthoud, C. Messiou, D. Cunningham, I. Chau, N. Starling, N. Turner, L. Welsh, R. L. Jones, J. Droney, S. Banerjee, K. Harrington, S. Bhide, A. Okines, A. Reid, S. Kumar. We thank the CAPTURE trial team, including E. Carlyle, K. Edmonds and L. Del Rosario, as well as H. Ahmod, L. Holt, M. O'Flaherty, D. Kelly, R. Dhaliwal, N. Ash, M. Mumin, L. Dowdie, K. Kelly, F. Williams, T. Foley, C. Lewis, M. Ndlovu, S. Ali, K. Lingard, S. Sarker, M. Mangwende, N. Hunter, J. Korteweg, A. Murra, N Shaikh , K. Peat, Mandisa Ndlovu, Kate Cullinan, Fiona Dexter and Nikhil Rudra. We thank the administrative team that delivered the RMH vaccine program, including E. Mossman and J. Codet-Boise. We thank the following for their assistance with trial conduct and. data collection, Laura A. Boos, Nalinie Joharatnam-Hogan, Wanyuan Cui, Javier Pascual, Simon Rodney, Justin Mencel, Olivia Curtis, Clemency Stephenson, Anna Robinson, Bhavna Oza, Sheima Farag, Isla Leslie, We thank clinical research network nurses for their input with consent and specimen collection including H. Evans, N. Evans, S. Cooper, S. Jain, S. White, L. Roland, L. Hobbs and J. Dobbyn. We acknowledge the tremendous support from clinical and research teams at participating units at the Royal Marsden Hospital, including E. Black, A. Dela Rosa, C. Pearce, J. Bazin, L. Conneely, C. Burrows, T. Brown, J. Tai, E. Lidington, H. Hogan, A. Upadhyay, D. Capdeferro, I. Potyka, A. Drescher, F. Baksh, M. Balcorta, C. Da Costa Mendes, J. Amorim, V. Orejudos and L. Davison.

We thank Prof. Wendy Barclay of Imperial College and the wider Genotype to Phenotype consortium for the Alpha and Delta strains used in this study, and Max Whiteley and Thushan I de Silva at The University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust for providing source material. We thank Prof. Gavin Screaton of the University of Oxford for the Omicron strain used in this study. We also thank volunteer staff at the Francis Crick Institute, the Crick COVID-19 Consortium.

Due to the pace at which the field is evolving, we acknowledge researchers of COVID-19, particularly those furthering our understanding of the COVID-19 vaccine-induced immune response. We apologise for the work that was not cited.

Journal Pre-proof

Journal Pre-proof

Author contributions

Conceptualization: Annika Fendler, Scott T.C. Shepherd, Lewis Au, Samra Turajlic

Data curation: Annika Fendler, Scott T.C. Shepherd, Lewis Au, Mary Wu, Ruth Harvey, Andreas M. Schmitt, Zayd Tippu, Benjamin Shum, Sheima Farag, Aljosja Rogiers, Tara Foley, Eleanor Carlyle, Kim Edmonds

Formal Analysis: Annika Fendler, Scott T.C. Shepherd, Lewis Au, Samra Turajlic

Funding acquisition: Annika Fendler, Lewis Au, Samra Turajlic

Investigation: Annika Fendler, Scott T.C. Shepherd, Lewis Au, Mary Wu, Ruth Harvey, Katalin Wilkinson, Taja Barber, Andrea Emslie-Henry, Niamh Caulfield-Lynch, Fiona Byrne, Daqi Deng, Svend Kjaer, Ok-Ryul Song, Christophe Queval, Caitlin Kavanagh, Kema Peat, Denise Kelly, Aida Murra, Kayleigh Kelly, Molly O'Flaherty, Nadia Yousaf, Shaman Jhanji, David Cunningham, Nicholas Van As, Kate Young, Andrew J.S. Furness, Lisa Pickering, Emma Nicholson, Samra Turajlic

Methodology: Annika Fendler, Mary Wu, Ruth Harvey, Katalin Wilkinson

Project administration: Annika Fendler, Scott T.C. Shepherd, Lewis Au, Eleanor Carlyle, Kim Edmonds, Lyra Del Rosario, Karla Lingard, Mary Mangwende, Lucy Holt, Hamid Ahmod, Justine Korteweg, Tara Foley, Samra Turajlic (oversight and governance)

Resources: Mary Wu, Ruth Harvey, Emma C. Wall, Edward J. Carr, Simon Caidan, James I MacRae, Robyn L. Shea, Gail Gardner, Darren Murray, Sonia Gandhi, Steve Gamblin, David L.V. Bauer, Kate C. Tatham, Susanna Walker, James Larkin, Samra Turajlic

Software: Mike Gavrielides,

Supervision: Gavin Kelly, Rupert Beale, Charles Swanton, George Kassiotis, Michael Howell, Emma Nicholson, Susanna Walker, Robert Wilkinson, James Larkin, Samra Turajlic

Validation: Annika Fendler, Scott T.C. Shepherd, Lewis Au, Emma C. Wall, Edward J. Carr, David L.V. Bauer, Mary Wu

Data verification: Annika Fendler, Scott T.C. Shepherd

Journal Pre-proof

Journal Pre-proof

Visualization: Annika Fendler, Scott T.C. Shepherd, Lewis Au, Samra Turajlic

Writing – original draft: Annika Fendler, Scott T.C. Shepherd, Lewis Au, Samra Turajlic

Writing – review & editing: All authors

Decision to submit manuscript: Samra Turajlic

Declaration of interests

The authors declare no competing interest.

Acknowledgements

Financial support: This research was funded in part by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust (RMCC32), Cancer Research UK (CRUK) (grant reference number C50947/A18176). This work was supported by the Francis Crick Institute, which receives its core funding from CRUK (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169, FC001030, FC011104), the UK Medical Research Council (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169, FC001030, FC011104), the Wellcome Trust (FC001988, FC001218, FC001099, FC001002, FC001078, FC001169, FC001030, FC011104), and the UK Research and Innovation and the UK Medical Research Council (MR/W005611/1). TRACERx Renal is partly funded by the NIHR Biomedical Research Centre at the Royal Marsden Hospital and the ICR (A109). The CAPTURE study is sponsored by the Royal Marsden NHS Foundation Trust and funded from a Royal Marsden Cancer Charity grant. A. Rogiers is supported by an ESMO clinical research fellowship. R.J.W. and K.A.W. receive support from Rosetrees (M926). A.F. has received funding from the European Union's Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement no. 892360. S.T.C.S. is supported and funded by a CRUK Clinician PhD Fellowship award. L.A. is funded by the Royal Marsden Cancer Charity. F.B. is funded by Rosetrees Charity (grant reference M829). S.T. is funded by CRUK (grant reference number C50947/A18176), the NIHR Biomedical Research Centre at the Royal Marsden Hospital and the Institute of Cancer Research (grant

Journal Pre-proof

Journal Pre-proof

reference number A109), the Kidney and Melanoma Cancer Fund of the Royal Marsden Cancer Charity, the Rosetrees Trust (grant reference number A2204), Ventana Medical Systems (grant reference numbers 10467 and 10530), the National Institutes of Health (US) and the Melanoma Research Alliance. A.M.S. received an educational grant from Janssen-Cilag. C. Swanton is funded by CRUK (TRACERx, PEACE and CRUK Cancer Immunotherapy Catalyst Network), the CRUK Lung Cancer Centre of Excellence (C11496/A30025), the Rosetrees Trust, Butterfield and Stoneygate Trusts, the Novo Nordisk Foundation (ID16584), a Royal Society Professorship Enhancement award (RP/EA/180007), the NIHR Biomedical Research Centre at University College London Hospitals, the CRUK University College London Centre, the Experimental Cancer Medicine Centre and the Breast Cancer Research Foundation (BCRF 20-157). This work was supported by a Stand Up To Cancer-LUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational research grant (grant number SU2C-AACR-DT23-17 to S.M. Dubinett and A.E. Spira). Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. C. Swanton received an ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020 research and innovation program (grant agreement no. 835297). C. Swanton is a Royal Society Napier Research Professor (RP150154). R.J.W. has received funding from the Francis Crick Institute, which receives its core funding by Wellcome (FC0010218), UKRI (FC0010218) and CRUK (FC0010218) and research funding from Wellcome (203135 and 222754), Rosetrees (M926) and the South African MRC. Graphical abstract created in BioRender.com.

INCLUSION AND DIVERSITY

We support inclusive, diverse, and equitable conduct of research.

Journal Pre-proof

Main figure titles and legends

Figure 1: NAb and T cell responses after a fourth vaccine dose and breakthrough infections

A) NAbT against Omicron BA.1, WT, and Delta were measured after fourth vaccine dose. NAbT below (IC50 titres <40) or above the quantitative range are (IC50 titres >2560) are indicated by horizontal lines. B) NAbT against Omicron BA.1, BA.2, WT, or Delta after four vaccine doses. Levels of C) $CD4^{+}CD137^{+}OX40^{+}$ or D) $CD8^{+}CD137^{+}CD69^{+}$ T cells in patients stimulated with WT or Omicron BA.1 full-length spike peptide pools after three or four vaccine doses. E) NAbT against Omicron BA.1, BA.2, WT, and Delta before and after breakthrough infection. Infections after two or three vaccine doses are displayed separately. Timing of blood sampling in relation to vaccination and infection is color-coded. The regression line and 95% CI was fitted using LOESS regression. Comparison of NAbT against Omicron BA.1, BA.2, WT, and Delta before infection (but after last vaccine dose) and after infection in patients with breakthrough infection after F) two and G) three vaccine doses. Violin plots denote the density of data, Pointrange denotes the median and the 25th and 75th percentile. Patients are indicated as individuals' data points and samples from individual patients are connected. The proportion of patients with detectable titres is visualised with a pie chart (dark blue denotes patients with IC50 titres >40). Biological replicates are patient subjects. There were no technical replicates.

Journal Pre-proof

Journal Pre-proof

Main tables and legends

Table 1: Baseline demographic, medical and oncological history of patients that received a fourth COVID-19 vaccine (n=80).

	4th COVID-19 vaccine dose cohort	AIM T cell assay subset
Patient demographics	**n=80**	**n= 39**
Age, years (median, IQR)	63 (55-70)	62 (54-69)
Male, n(%)	47 (59)	24 (62)
Ethnicity, white, n(%)	67 (84)	33 (85)
Vaccination and prior SARS-CoV-2 infection		
1st and 2nd COVID-19 vaccine, n (%)		
ChAdOx1	45 (56)	24 (62)
BNT162b2	35 (44)	15 (38)
3rd and 4th COVID-19 vaccine, n(%)		
BNT162b2	80 (100)	39 (100)
Time from 3rd to 4th vaccine dose, days (median, IQR)	92 (86-96)	93 (85-97)
Previous SARS-CoV-2 infection, n(%)		
Any time before 2nd vaccine	11 (14)	3 (8)
Cancer and treatment history		
Cancer type, n(%)		
Solid cancer	0 (0)	0 (0)
Blood cancer	80 (100)	39 (100)
Diagnosis, n(%)		
Lymphoma	21 (26)	14 (36)
Myeloma	33 (41)	11 (28)
CLL	16 (20)	12 (31)
Acute Leukaemia	7 (9)	2 (5)
Myelodysplastic syndrome	3 (4)	0 (0)
Cancer Status, n(%)		
Complete response to SACT/remission	37 (46)	16 (41)
Never treated	9 (11)	5 (13)
Progressive disease on SACT/relapse	9 (11)	8 (21)
Partial response to SACT/remission	22 (28)	9 (23)
Stable disease	2 (3)	1 (3)
Rx prior to 1st vaccine dose, n(%)		
Chemotherapy, <28 days	6 (8)	3 (8)
Targeted therapy, <28 days	25 (31)	8 (21)
Anti-CD20 mAb, <12 mths	9 (11)	6 (15)
BTKi therapy, <28 days	4 (5)	3 (8)
No recent SACT	47 (59)	25 (64)
HSCT, ever	37 (46)	15 (38)
Autograft, ever	23 (29)	10 (26)
Allograft, ever	14 (18)	5 (13)
HSCT, <6 months	4 (5)	1 (3)
CAR-T, <6 months	2 (3)	2 (5)
Rx prior to 4th vaccine dose, n(%)		
Chemotherapy, <28 days	8 (10)	3 (8)
Targeted therapy, <28 days	30 (38)	9 (23)
Anti-CD20 mAb, <12 mths	11 (14)	8 (21)
BTKi therapy, <28 days	4 (5)	3 (8)
No recent SACT	38 (48)	24 (62)

Activation induced marker (AIM) T cell assay was performed in a subset of 39 patients. Values are numbers and percentages n(%) unless otherwise stated. AIM, activation induced marker; BTK-I, Bruton's tyrosine kinase inhibitor; CAR-T, chimeric

Journal Pre-proof

Journal Pre-proof

antigen receptor T cell; CLL, chronic lymphocytic leukaemia; HSCT, hematopoietic stem cell transplant; IQR, interquartile range; mAB, monoclonal antibody; Rx, treatment; SACT, systemic anti-cancer therapy.

Table 2: Baseline demographic, clinical and oncological history for 51 patients with a history of breakthrough infection (defined as a positive SARS-CoV-2 RT-PCR or lateral flow test at least 7 days following the second COVID-19 vaccination).

		Timing of breakthrough infection	
	Breakthrough infection cohort	After 2nd but before 3rd vaccine	After 3rd or 4th vaccine
Patient demographics	n=57	n=36	n=21
Age, years (median, IQR)	52 (50-68)	51 (46-68)	63 (56-67)
Male, n(%)	30 (53)	15 (42)	15 (71)
Ethnicity, white, n(%)	49 (86)	30 (83)	19 (90)
COVID-19 vaccination and prior infection			
1st and 2nd COVID-19 vaccine, n (%)			
ChAdOx1	33 (58)	25 (69)	8 (38)
BNT162b2	24 (42)	11 (31)	13 (61)
3rd COVID-19 vaccine, n(%)			
ChAdOx1	0 (0)	0 (0)	0 (0)
BNT162b2	44 (77)	23 (64)	21 (100)
No 3rd vaccine	13 (23)	13 (36)	-
SARS-CoV-2 infection history, n(%)			
SARS-CoV-2 prior to 2nd vaccination	2 (4)	1 (3)	1 (5)
Breakthrough infection			
Time from last vaccine dose to infection, median (IQR)	79 (66-139)	111 (65-153)	74(67-88)
Samples available, yes, n(%)			
Between most recent vaccination and infection	26	12	14
Post-infection	50	35	15
WHO severity score, n(%)			
Asymptomatic (WHO score 1)	9 (16)	6 (17)	3 (14)
Mild (WHO score 2-3)	42 (74)	25 (69)	17 (81)
Moderate (WHO score 4-6)	2 (4)	2 (6)	0 (0)
Severe (WHO score 6-10)	4 (7)	3 (8)	1 (5)
Symptoms, n(%)			
Anosmia	13 (23)	10 (28)	3 (14)
Coryza	20 (35)	9 (25)	11 (52)
Cough	29 (51)	17 (48)	12 (57)
Fatigue	16 (28)	9 (25)	7 (33)
Fever	22 (39)	15 (42)	7 (33)
GI symptoms	6 (11)	3 (8)	3 (14)
Headache	6 (11)	3 (8)	3 (14)
Shortness of breath	15 (26)	11 (31)	4 (19)
Medical management for COVID-19, n(%)			
Hospitalisation for treatment of COVID-19	6 (11)	5 (14)	1 (5)
Supplemental oxygen therapy	5 (9)	4 (14)	1 (5)
Dexamethasone	5 (9)	4 (11)	1 (5)
IL-6 mAB	3 (5)	3 (8)	0 (0)
Antiviral therapy*	8 (14)	3 (8)	5 (24)
Death within 28 days of positive SARS-CoV-2 test, (n%)	4 (5)	3 (8)	1 (5)
Cancer and treatment history			
Cancer diagnosis and stage, n(%)			
Solid cancer stage I-III	13 (23)	12 (33)	1 (5)
Solid cancer stage IV	28 (49)	21 (58)	7 (33)
Blood cancer	16 (28)	3 (8)	13 (62)
Cancer status with respect to most recent treatment at time of infection, n(%)			
Complete response to SACT/remission	10 (18)	4 (11)	6 (29)
Progressive disease on SACT/relapse	17 (30)	12 (33)	5 (24)
Partial response to SACT/remission	13 (23)	7 (19)	6 (29)

Journal Pre-proof

Stable disease to SACT	6 (11)	4 (11)	2 (10)
Complete resection/NED	11 (19)	9 (25)	2 (10)
Rx prior to SARS-CoV-2 infection, n(%)			
Chemotherapy, <28 days	13 (23)	9 (25)	4 (19)
Targeted therapy, <28 days	17 (30)	10 (28)	7 (33)
Anti-PD-(L)1 ± anti-CTLA-4, <6 months	7 (12)	7 (19)	0 (0)
Anti-CD20 mAb, <12 mths	3 (5)	1 (3)	2 (10)
HSCT, ever	4 (7)	0 (0)	4 (19)
Other medication			
Corticosteroids	4 (7)	4 (11)	0 (0)

Patients are split according to timing of breakthrough infection relative to second or third COVID-19 vaccination. Values are numbers and percentages n(%) unless otherwise stated. *Antiviral therapies included Sotrovimab (n=2), Remdesivir (n=4) and Molnupiravir (n=2). BTK-I, Bruton's tyrosine kinase inhibitor; CAR-T, chimeric antigen receptor T cell; CLL, chronic lymphocytic leukaemia; COVID-19, coronavirus disease 2019; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; HSCT, hematopoietic stem cell transplant; IL-6, interleukin-6; IQR, interquartile range; mAB, monoclonal antibody; NED, no evidence of disease; Rx, treatment; PD-L1, programmed death ligand -1; SACT, systemic anti-cancer therapy.

Table 3: Association of clinical parameters with detectable NAb against Omicron

		Detectable NAb against Omicron BA.1		Detectable NAb against Omicron BA.2	
	Patients (n)	**OR (95%CI)**	**p-value**	**OR (95%CI)**	**p-value**
Blood cancer patients, n=80					
Intercept		2.80 (0.68-15.17)	0.26	3.54 (0.78-23.45)	0.21
Diagnosis (vs Acute leukaemia)					
Chronic lymphocytic leukaemia	16/80	3.48 (0.46-2.45)	0.30	7.41 (0.78-109.31)	0.16
Myelodysplastic syndrome	3/80	1.21 (0.06-28.03)	0.91	NA	0.99
Myeloma	33/80	9.53 (0.88-131.13)	0.13	NA	0.99
Lymphoma	21/80	8.07 (0.88-97.32)	0.13	2.49 (1.90-606.61)	0.06
Vaccine Type (1st and 2nd dose)					
BNT162b2 (vs ChAdOx1)	35/80	0.46 (0.13-1.61)	0.31	0.28 (0.04-1.47)	0.23
Previous COVID-19					
SARS-CoV-2 infection before second vaccine dose	11/80	6.52 (1.13-51.90)	0.10	4.08 (0.52-57.99)	0.30
Anti-cancer therapy†					
B-cell depleting therapy (anti-CD20 [within 12 months] or BTKi [within 28 days])	15/80	0.03 (0.003-0.14)	0.0013*	0.06(0.004-0.41)	0.04
Chemo- or targeted therapy	34/80	0.68 (0.10-4.17)	0.74	0.55 (0.03-11.24)	0.72

NAb were binned in detected (>= 40) or undetected (<40) †For anti-cancer therapy indicated treatment was tested for patients who received the treatment vs patients not receiving that treatment. BTKi, Bruton's tyrosine kinase inhibitor.

Journal Pre-proof

Journal Pre-proof

Journal Pre-proof

STAR METHODS

RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Samra Turajlic (samra.turajlic@crick.ac.uk).

Materials availability
All requests for resources and reagents should be directed to the lead contact author. All reagents will be made available on request after completion of a Materials Transfer Agreement.

Data and code availability

- **Data:** All data reported in this paper will be shared by the lead contact upon request.
- **Code:** This paper does not report original code.
- **Additional information:** Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Study design

CAPTURE (NCT03226886) is a prospective, longitudinal cohort study that commenced recruitment in May 2020 at the Royal Marsden NHS Foundation Trust. Adult patients with a current diagnosis or history of invasive cancer are eligible for enrolment [26]. Inclusion criteria are intentionally broad, and patients were recruited irrespective of cancer type, stage, or treatment. The primary endpoint of the CAPTURE study was the seroconversion rate in cancer patients at 14-28 days following the second dose of vaccine [27]. Exploratory endpoints include evaluation of neutralising responses to SARS-CoV-2 variants of concern (VOC).

CAPTURE received ethical approval as a substudy of the TRACERx Renal Study (NCT03226886). TRACERx Renal was initially approved by the NRES Committee London, Fulham, on January 17, 2012 (11/LO/1996). The CAPTURE protocol was part of Substantial Amendment 9 and received approval by the Health Research Authority on April 30, 2020, and the NRES Committee London, Fulham on May 1, 2020. CAPTURE is conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice and applicable regulatory requirements. All patients provided written, informed

Journal Pre-proof

consent to participate. The Chief Investigator, Samra Turajlic is responsible for the oversight of all aspects of study conduct and governance.

Study schedule and follow-up

Detailed sampling schedule and methodology were described previously [26]. Patients eligible for a third and fourth vaccine dose were invited to receive the vaccine in our institution. Samples were collected following the third vaccine dose (Post-V3; 14-28 days post third vaccination) and following fourth vaccine dose (Post-V4; 7-28 days post fourth vaccine dose).

The study protocol did not mandate screening for breakthrough SARS-CoV-2 infections and all breakthrough infections were detected during the course of routine clinical care. Where breakthrough infections were reported, an additional post-infection blood sample was sought at least 14 days following the positive SARS-CoV-2 test.

Patient data

Demographic, epidemiological and clinical data (e.g. cancer type, cancer stage, treatment history, history of SARS-CoV-2 infection) were collected from the internal electronic patient record and prospectively from patients. Pseudonymised data was entered into a cloud-based electronic database (Ninox Software, Berlin, Germany). Chemotherapy, targeted therapy (small molecule inhibitors or monoclonal antibodies) or endocrine therapy was deemed to be current if given within 28 days of vaccination. Treatment with immune checkpoint inhibitors (CPI) within six months was considered significant given the prolonged receptor occupancy reported with these agents [28]. Treatment with ant-CD20 monoclonal antibodies within 12 months was considered. Concomitant medications were recorded for: corticosteroids (considered significant if >10mg prednisolone equivalent given for at least seven days); GCSF when delivered within 48 hours of vaccination or five days in the case of pegylated preparation; and other immunosuppressive drugs taken within 48 hours of vaccination.

Journal Pre-proof

Definition of breakthrough SARS-CoV-2 infection

We considered patients to have had a breakthrough SARS-CoV-2 infection if they had SARS-CoV-2 positive RT-PCR (tests conducted as part of routine clinical care) at least seven days following the second COVID-19 vaccine dose. Breakthrough infections after the second vaccine dose were considered delta infections while breakthrough infections after the third vaccine dose were considered omicron infections based on the high prevalence of the respective variants at the time.

WHO classification of severity of COVID-19

We classified the severity of COVID-19 according to the WHO ordinal clinical progression scale [29]. Uninfected: uninfected, no viral RNA detected – 0; Asymptomatic: viral RNA and/or S1-reactive IgG detected – 1; mild (ambulatory): symptomatic, independent – 2; symptomatic, assistance needed - 3; moderate (hospitalised): no oxygen therapy (if hospitalised for isolation only, record status as for ambulatory patient) – 4; oxygen by mask or nasal prongs - 5; severe (hospitalised): oxygen by non-invasive ventilation or high flow – 6; intubation and mechanical ventilation, $pO_2/FiO_2 \geq 150$ or $SpO_2/FiO_2 \geq 200$ – 7; mechanical ventilation, $pO_2/FiO_2 < 150$ ($SpO_2/FiO_2 < 200$) or vasopressors – 8; mechanical ventilation, $pO_2/FiO_2 < 150$ and vasopressors, dialysis, or extracorporeal membrane oxygenation - 9; Dead - 10.

Journal Pre-proof

Handling of whole blood samples

All blood samples and isolated products were handled in a CL2 laboratory inside a biosafety cabinet using appropriate personal protective equipment and safety measures, in accordance with a risk assessment and standard operating procedure approved by the safety, health and sustainability committee of the Francis Crick Institute.

Primary cells: PBMC and plasma isolation from whole blood

All primary cells in this study were procured from CAPTURE participants. Whole blood was collected in EDTA tubes (VWR) and stored at 4ºC until processing. All samples were processed within 24 hours.

Journal Pre-proof

Time of blood draw, processing, and freezing was recorded. Prior to processing, tubes were brought to room temperature (RT). PBMC and plasma were isolated by density-gradient centrifugation using pre-filled centrifugation tubes (pluriSelect). Up to 30 ml of undiluted blood was added on top of the sponge and centrifuged for 30 minutes at 1000g at RT. Plasma was carefully removed then centrifuged for 10 minutes at 4000g to remove debris, aliquoted and stored at -80ºC. The cell layer was then collected and washed twice in PBS by centrifugation for 10 minutes at 300g at RT. PBMC were resuspended in Recovery cell culture freezing medium (Fisher Scientific) containing 10% DMSO, placed overnight in freezing containers (Corning) at -80ºC and then transferred for long-term storage in liquid nitrogen. PBMCs for in vitro stimulation were thawed at 37 °C and resuspended in 10 ml of warm complete medium (RPMI and 5% human AB serum) containing 0.02% benzonase. 2×10^6 cells were seeded in 200 µl complete medium in 96-well plates and cultured for 24 h at 37 °C, 5% CO_2.

Journal Pre-proof

Serum isolation

Whole blood was collected in serum coagulation tubes (Vacuette CAT tubes, Greiner) for serum isolation and stored at 4ºC until processing. All samples were processed within 24 hrs. Time of blood draw, processing, and freezing was recorded. Tubes were centrifuged for 10 minutes at 2000g at 4ºC. Serum was separated from the clotted portion, aliquoted and stored at -80ºC.

Cell lines and culture

Vero E6 cells were kindly provided by Dr Björn Meyer, Institut Pasteur, Paris, France. Cells were grown in Iscove's Modified Dulbecco's Medium (Sigma-Aldrich) supplemented with 5% fetal bovine serum (Thermo Fisher Scientific), L-glutamine (2 mM, Thermo Fisher Scientific), penicillin (100 U/ml, Thermo Fisher Scientific), and streptomycin (0.1 mg/ml, Thermo Fisher Scientific).

METHOD DETAILS

Virus variants

Journal Pre-proof

The SARS-CoV-2 reference isolate (referred to as 'WT') was hCoV19/England/02/2020, obtained from the Respiratory Virus Unit, Public Health England (GISAID EpiCov accession, EPI_ISL_407073). The B.1.617.2 ("Delta") isolate was MS066352H (GISAID accession number EPI_ISL_1731019), which carries the T19R, K77R, G142D, Δ156-157/R158G, A222V, L452R, T478K, D614G, P681R, D950N, and was kindly provided by Prof. Wendy Barclay, Imperial College London, London, UK through the Genotype-to-Phenotype National Virology Consortium (G2P-UK). The BA.1 ("Omicron") isolate was M21021166, which carries the A67V, Δ69-70, T95I, Δ142-144, Y145D, Δ211, L212I, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, A701V, N764K, D796Y, N856K, Q954H, N969K, and L981F mutations in Spike. It was kindly provided by Prof. Gavin Screaton, University of Oxford, Oxford, UK through the Genotype-to-Phenotype National Virology Consortium (G2P-UK). The BA.2 isolate was Crick179, isolated from a nasopharyngeal swab collected from a participant in the UCLH-Crick Legacy study [7-9]. Swabs were collected in Vital-Transport medium (VTM), transported, and stored at 4 degrees prior to viral culture. This isolate carries the T19I, L24_A27del, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H mutations in Spike. All viral isolates were propagated in Vero E6 cells. Briefly, 50% confluent monolayers of Vero E6 cells were infected with the given SARS CoV-2 strains at an MOI of approx. 0.001. Cells were washed once with DMEM (Sigma; D6429), then 5 ml virus inoculum made up in DMEM was added to each T175 flask and incubated at room temperature for 30 minutes. DMEM + 1% FCS (Biosera; FB-1001/500) was added to each flask. Cells were incubated at 37° C, 5% CO^2 for four days until the extensive cytopathogenic effect was observed. The supernatant was harvested and clarified by centrifugation at 2000 rpm for 10 minutes in a benchtop centrifuge. The supernatant was aliquoted and frozen at -80°C.

Virus PCR and sequencing

Journal Pre-proof

All virus stocks generated for use in neutralisation assays were sequence-validated before use. To confirm the identity of cultured VoC samples, 8ul of viral RNA was prepared for sequencing by the ARTIC method (https://www.protocols.io/view/ncov-2019-sequencingprotocol-v3-locost-bh42j8ye) and sequenced on the ONT GridION platform to >30k reads/sample. The data was demultiplexed and processed using the viralrecon pipeline (https://github.com/nf-core/viralrecon).

High-throughput live virus micro-neutralisation assay

High-throughput live virus micro-neutralisation assays were performed as described previously [30]. Briefly, Vero E6 cells (Institute Pasteur) at 90-100% confluency in 384-well format were first titrated with varying MOI of each SARS-CoV-2 variant and varying concentrations of a control monoclonal nanobody to normalise for possible replicative differences between variants and select conditions equivalent to wild-type virus. Following this calibration, cells were infected in the presence of serial dilutions of patient serum samples. After infection (24 hrs), cells were fixed with 4% final Formaldehyde, permeabilised with 0.2% TritonX-100, 3% BSA in PBS (v/v), and stained for SARS-CoV-2 N protein using Alexa488-labelled-CR3009 antibody produced in-house and cellular DNA using DAPI [31]. Whole-well imaging at 5x was carried out using an Opera Phenix (Perkin Elmer) and fluorescent areas and intensity calculated using the Phenix-associated software Harmony 9 (Perkin Elmer). Inhibition was estimated from the measured area of infected cells/total area occupied by all cells. The inhibitory profile of each serum sample was estimated by fitting a 4-parameter dose-response curve executed in SciPy. Neutralising antibody titres are reported as the fold-dilution of serum required to inhibit 50% of viral replication (IC_{50}). They are further annotated if they lie above the quantitative (complete inhibition) range, below the quantitative range but still within the qualitative range (i.e. partial inhibition is observed, but a dose-response curve cannot be fit because it does not sufficiently span the IC_{50}), or if they show no inhibition at all. IC_{50} values above the quantitative limit of detection of the assay (>2560) were recoded as 3000; IC_{50} values below the quantitative limit of the assay (< 40)

Journal Pre-proof

but within the qualitative range were recoded as 39 and data below the qualitative range (i.e. no response observed) were recoded as 10.

PBMC stimulation assay

PBMCs for in vitro stimulation were thawed at 37 °C and resuspended in 10 ml of warm complete medium (RPMI and 5% human AB serum) containing 0.02% benzonase. 2 × 10^6 cells were seeded in 200 µl complete medium in 96-well plates. Cells were stimulated with 4 µl per well PepTivator SARS-CoV-2 spike (S) (Miltenyi Biotec) (synthetic SARS-CoV-2 peptide pools, consisting of 15-mer sequences with 11 amino acid overlap covering the complete S protein), or a custom Omicron BA.1 spike peptide pool (Pepscan) (15-mer sequences with 11 amino acids overlap covering the complete S-protein) representing 1 µg ml−1 final concentration per peptide. SEB (Merck, UK) was used as a positive control at 0.5 µg ml−1 final concentration, negative control was PBS containing dimethylsulfoxide at 0.002% final concentration. PBMCs were cultured for 24 h at 37 °C, 5% CO2.

Activation-induced marker assay

Cells were washed twice in warm PBMC medium. Dead cells were stained with 0.5 µl per well Zombie dye V500 for 15 min at room temperature in the dark, then washed once with PBS containing 2% FCS (FACS buffer). A surface staining mix was prepared, containing 1 µl per well of each antibody in 50:50 brilliant stain buffer (BD) and FACS buffer. PBMCs were stained with 50 µl surface staining mix for 30 min at room temperature in the dark. Cells were washed once in FACS buffer and fixed in 1% PFA in FACS buffer for 20 min, then washed once and resuspended in 200 µl PBS. All samples were acquired on a Bio-Rad Ze5 flow cytometer running Bio-Rad Everest software v.2.4 and analyzed using FlowJo v.10.7.1 (Tree Star). Compensation was performed with 20 µl antibody-stained anti-mouse Ig, κ/ negative control compensation particle set (BD Biosciences). A total of 1 × 10^6 live $CD3^+CD19^-CD14^-$ cells were acquired per sample. Gates were drawn relative to the unstimulated control for each donor. CD137 and OX40 were used to quantify $CD4^+$ T cell activation, CD137 and CD69 were used for $CD8^+$ T

cell activation. T cell response are reported as a stimulation index by dividing the percentage of activation-induced marker (AIM)-positive cells by the percentage of cells in the negative control. If negative control was 0, then the minimum value across the cohort was used. A 2-fold increase in stimulation index was considered positive.

QUANTIFICATION AND STATISTICAL ANALYSIS

Data and statistical analysis were done in R v3.6.1 in R studio v1.2.1335. McNemar and Wilcoxon Mann-Whitney-U test were used to evaluate statistical significance. A p-value <0.05 was considered significant. All tests were performed two-sided. Statistical details for each experiment are provided in the figure legends. The ggplot2 package in R was used for data visualisation. Data are usually plotted as single data points and violin plots on a logarithmic scale. PointRange in violin plots denotes median and upper and lower quartiles. For breakthrough infection trends in NAbT are visualised with a loess regression curve. Multivariable binary logistic regression analysis was performed using the glm function within the stats package in R, OR and 95% CI were generated using the coef and confint function within the stats package in R. Covariates included in the model were selected based on previously reported effects on NAb responses after two or three doses of COVID-19 vaccine. The reference was chosen for covariates with multiple categories to reflect the group with the least expected effect on NAb response. Anti-CD20 and BTKi treatments were combined in a single covariate based on their similar effect on B cell levels. Other treatments were combined to a single variable based on previous experience of their limited impact [1, 4, 27]

ADDITIONAL RESOURCES

Clinical trial registry number: NCT03226886

Journal Pre-proof

Journal Pre-proof

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
V500 Mouse Anti-Human CD14	BD	Cat#561391
V500 Mouse anti-Human CD19	BD	Cat#561121
Brilliant Violet 605 anti-human CD4 Antibody	Biolegend	Cat#317438
Brilliant Violet 650™ anti-human CD8a Antibody	Biolegend	Cat#301042
PE-CF594 Mouse Anti-Human CD69	BD	Cat#562617
PE/Cyanine7 anti-human CD134 (OX40) Antibody	Biolegend	Cat#350012
APC anti-human CD137 (4-1BB) Antibody	Biolegend	Cat#309810
Alexa Fluor® 700 anti-human CD3 Antibody	Biolegend	Cat#317340
Alexa488-labelled-CR3009 anti-SARS-CoV-2 Ab	produced in-house	
CD3022 anti-SARS-CoV-2 Ab	Absolute Antibodies	Cat#Ab01680-10.0
Bacterial and Virus Strains		
MS066352H - B.1.617.2 (“Delta”) isolate	Prof. Wendy Barclay, Imperial College London, London, UK	GISAID accession number: EPI_ISL_1731019
M21021166 - BA.1 (“Omicron”) isolate	Prof. Gavin Screaton, University of Oxford, Oxford, UK	
Crick179 - BA.2 isolate	Emma Wall, Mary Wu, The Francis Crick Institute, London, UK	
hCoV19/England/02/2020 - "WT" SARS-CoV-2 isolate	Respiratory Virus Unit, Public Health England	GISAID accession number: EPI_ISL_407073
MS066352H - B.1.617.2 (“Delta”) isolate	Prof. Wendy Barclay, Imperial College London, London, UK	GISAID accession number: EPI_ISL_1731019
M21021166 - BA.1 (“Omicron”) isolate	Prof. Gavin Screaton, University of Oxford, Oxford, UK	
Crick179 - BA.2 isolate	Emma Wall, Mary Wu, The Francis Crick Institute, London, UK	
hCoV19/England/02/2020 - "WT" SARS-CoV-2 isolate	Respiratory Virus Unit, Public Health England	GISAID accession number: EPI_ISL_407073
Experimental models: Cell lines		
VERO-E6	Dr Björn Meyer, Institut Pasteur, Paris, France[30]	
Peripheral blood mononuclear cells (primary cells)	CAPTURE study participants	NCT03226886
Chemicals, Peptides, and Recombinant Proteins		
Custom omicron BA.1 peptide pool (15-mer sequences with 11 amino acids overlap covering the complete S-protein)	Pepscan	Cat#8907693

PepTivator SARS-CoV-2 spike (S) (Miltenyi Biotec) (synthetic SARS-CoV-2 peptide pools, consisting of 15-mer sequences with 11 amino acid overlap covering the complete S protein)	Miltenyi Biotec	Cat#130-126-700

Journal Pre-proof

Journal Pre-proof

REFERENCES

1. Fendler A, Shepherd, S.T.C., Au, L., Wilkinson, K.A., Wu, M., Schmitt, A.M., Tippu, Z., Farag, S., Rogiers, A., Ruth, H.,. Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancer. *Cancer Cell* 2022; 40. DOI: https://doi.org/10.1016/j.ccell.2021.12.013.

2. Shapiro LC, Thakkar A, Campbell ST, et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. *Cancer Cell* 2022; 40: 3-5. DOI: https://doi.org/10.1016/j.ccell.2021.11.006.

3. Aleman A, Van Oekelen O, Upadhyaya B, et al. Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. *Cancer Cell*. DOI: 10.1016/j.ccell.2022.03.013.

4. Fendler A, Shepherd STC, Au L, et al. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. *The Lancet* 2022; 399: 905-907. DOI: https://doi.org/10.1016/S0140-6736(22)00147-7.

5. Xia S, Wang L, Zhu Y, et al. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. *Signal Transduction and Targeted Therapy* 2022; 7: 241. DOI: 10.1038/s41392-022-01105-9.

6. ONS. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/preexistingconditionsofpeoplewhodiedduetocovid19englandandwales, https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/preexistingconditionsofpeoplewhodiedduetocovid19englandandwales (2022).

7. Wall EC, Wu M, Harvey R, et al. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. *The Lancet* 2021; 398: 207-209. DOI: 10.1016/S0140-6736(21)01462-8.

8. Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *The Lancet* 2021; 397: 2331-2333. DOI: https://doi.org/10.1016/S0140-6736(21)01290-3.

9. Wu M, Wall EC, Carr EJ, et al. Three-dose vaccination elicits neutralising antibodies against omicron. *The Lancet* 2022. DOI: https://doi.org/10.1016/S0140-6736(22)00092-7.

10. Fendler A, Au L, Shepherd STC, et al. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. *Nature Cancer* 2021; 2: 1321-1337. DOI: 10.1038/s43018-021-00275-9.

11. Richardson SI, Madzorera VS, Spencer H, et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated individuals. *medRxiv* 2022: 2022.2002.2010.22270789. DOI: 10.1101/2022.02.10.22270789.

12. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. *New England Journal of Medicine* 2021. DOI: 10.1056/NEJMoa2109072.

13. Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. *New England Journal of Medicine* 2022; 386: 1377-1380. DOI: 10.1056/NEJMc2202542.

14. Mair MJ, Mitterer M, Gattinger P, et al. Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron. *Cancer Cell* 2022. DOI: 10.1016/j.ccell.2022.04.003.

Journal Pre-proof

15. Chaguza C, Coppi A, Earnest R, et al. Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons. *Med* 2022. DOI: https://doi.org/10.1016/j.medj.2022.03.010.

16. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. *New England Journal of Medicine* 2022. DOI: 10.1056/NEJMoa2200797.

17. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *New England Journal of Medicine* 2022. DOI: 10.1056/NEJMoa2119451.

18. Baum U, Poukka E, Leino T, et al. High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron. *medRxiv* 2022: 2022.2003.2011.22272140. DOI: 10.1101/2022.03.11.22272140.

19. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. *BMJ* 2022; 376: e069761. DOI: 10.1136/bmj-2021-069761.

20. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by 4th dose of BNT162b2 against Omicron in Israel. *medRxiv* 2022: 2022.2002.2001.22270232. DOI: 10.1101/2022.02.01.22270232.

21. Ronen A, Ruslan S, Michael F, et al. Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old. *Research Square* 2022. Preprint. DOI: 10.21203/rs.3.rs-1478439/v1.

22. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature Medicine* 2021; 27: 1205-1211. DOI: 10.1038/s41591-021-01377-8.

Journal Pre-proof

Journal Pre-proof

23. Yao L, Zhu K-L, Jiang X-L, et al. Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection. *The Lancet Infectious Diseases* 2022; 22: 1116-1117. DOI: 10.1016/S1473-3099(22)00410-8.

24. Bowen JE, Addetia A, Dang HV, et al. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. *Science* 2022; 377: 890-894. DOI: doi:10.1126/science.abq0203.

25. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature* 2022; 602: 657-663. 20211223. DOI: 10.1038/s41586-021-04385-3.

26. Au L, Boos LA, Swerdlow A, et al. Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study. *Cell* 2020; 183: 4-10. DOI: https://doi.org/10.1016/j.cell.2020.09.005.

27. Fendler A, Shepherd STC, Au L, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. *Nature Cancer* 2021; 2: 1305-1320. DOI: 10.1038/s43018-021-00274-w.

28. Fessas P, Lee H, Ikemizu S, et al. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. *Semin Oncol* 2017; 44: 136-140. 2017/09/20. DOI: 10.1053/j.seminoncol.2017.06.002.

29. Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. *The Lancet Infectious Diseases* 2020; 20: e192-e197. DOI: 10.1016/S1473-3099(20)30483-7.

30. Faulkner N, Ng KW, Wu MY, et al. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. *eLife* 2021; 10: e69317. DOI: 10.7554/eLife.69317.

Journal Pre-proof

31. van den Brink Edward N, ter Meulen J, Cox F, et al. Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus. *Journal of Virology* 2005; 79: 1635-1644. DOI: 10.1128/JVI.79.3.1635-1644.2005.

Journal Pre-proof

Journal Pre-proof















Journal Pre-proof

Title

Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

Highlights

- Increased neutralising antibody (NAb) responses following 4th COVID-19 vaccine dose
- SARS-CoV-2 specific T cell responses increased following 4th COVID-19 dose
- NAb responses reduced to Omicron BA.1 and BA.2 lineages compared to wild-type
- B cell depleting therapy within 12 months associated with undetectable NAb

Each <85 characters

eTOC Blurb

Fendler et al evaluate neutralising antibody (Nab) and cellular responses to a fourth COVID-19 vaccination in patients with blood cancer. The proportion of patients with detectable NAb and T cell responses increased after the fourth vaccine dose however some had suboptimal NAb responses, in particular those receiving B-cell depleting therapies.

Word count 50/50 words

Journal Pre-proof